Supplementary Figure S2: Expressions of DR5 mRNA and cell-surface DR5 are different between two bladder cancer cell lines. from A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells

Abstract

<p>T24 or UM-UC-11 cells were treated with the indicated concentrations of OBP-801 and/or celecoxib for 48 h in T24 cells or 72 h in UM-UC-11 cells. A. Quantitative real-time RT-PCR of DR5 mRNA. The internal control was β2MG. Values show fold change in DR5 expression compared with control (DMSO treatment). Data represent the means of triplicates with SD. B. Cells were stained with PE-labeled mouse anti-human DR5 monoclonal antibody and PE-labeled IgG isotype control. Data were analyzed by flow cytometry. Overlaid histogram is shown in the upper panels. DMSO treatment (gray histogram), OBP-801 treatment (dashed line), celecoxib treatment (dotted line), and combined treatment (solid line). In the lower panels, values show fold change of the geometric mean values in the expression of DR5/IgG. Columns, means of triplicate data; bars, SD; **, P<0.01.</p>